Northwest Biotherapeutics Inc (NWBO) stock
Close on Oct 19, 2026Market cap $265.44MP/E –Yield –
Northwest Biotherapeutics Inc grew revenue 204.8% to $2.86M over the twelve months to Sep 30, 2026. Free cash flow was -$44.49M. At the latest close the market valued the company at $265.44M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $265.44M
- P/E ratio
- –
- Price to sales
- 92.94
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -16.76%
Fundamentals
- Revenue
- $2.86M
- Net income
- -$39.66M
- EPS, diluted
- -$0.03
- Free cash flow
- -$44.49M
- Book value per share
- -$0.03
- Diluted shares
- 1.71B
Trading
- Previous close
- $0.16
- Open
- $0.16
- Day's range
- $0.15 – $0.16
- Volume
- 4,330,788
- Average volume (20 days)
- 5,253,376
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | NWBO | S&P 500 | Difference | NWBO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.1% | +0.6% | −3.7 pts | ||
| 3 months | -8.1% | +3.4% | −11.4 pts | ||
| Year to date | -32.2% | +13.3% | −45.5 pts | ||
| 1 year | -32.3% | +16.6% | −48.9 pts | ||
| 3 years | -77.5% | +86.4% | −163.9 pts | -39.2% | +23.1% |
| 5 years | -86.9% | +81.9% | −168.7 pts | -33.4% | +12.7% |
| 10 years | -70.7% | +318.9% | −389.6 pts | -11.6% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
About Northwest Biotherapeutics
Pharmaceutical Preparations
Northwest Biotherapeutics is a biotechnology company that develops personalized immune therapies for cancer patients. Its platform technology, DCVax, utilizes a patient's activated dendritic cells to stimulate their immune system against cancer. The company's lead product candidate, DCVax-L, targets surgically removable solid tumors such as glioblastoma multiforme brain cancer. Another product candidate, DCVax-Direct, is designed to treat inoperable solid tumors across a range of cancer types. The company operates within the biopharmaceutical sector, focusing on cancer patients.
Company profile, executives and historyNorthwest Biotherapeutics stock: common questions
What is Northwest Biotherapeutics's stock price?
NWBO closed at $0.16 on Oct 19, 2026, down 0.88% on the day.
What is Northwest Biotherapeutics's market cap?
Northwest Biotherapeutics was worth $265.44M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is NWBO's P/E ratio?
Northwest Biotherapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.03), so it has no meaningful P/E ratio.
How much revenue does Northwest Biotherapeutics make?
Northwest Biotherapeutics reported revenue of $2.86M for the twelve months to Sep 30, 2026, up 204.8% from a year earlier.
Does Northwest Biotherapeutics pay a dividend?
No. Northwest Biotherapeutics has not paid a cash dividend over the last twelve months.
How has NWBO stock performed over the past year?
Including dividends, NWBO returned -32.3% over the past year, against +16.6% for the S&P 500.
Who are Northwest Biotherapeutics's competitors?
Companies most similar to Northwest Biotherapeutics by business, industry and size include BOLT, IMNM, DNTH, XBIO, MRKR.
See a number that looks wrong?